A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)

Conditions

COVID-19 Inpatient | COVID-19 Outpatient

Phase COVID-III

Volunteers
Health Professionals

What is the purpose of this trial?

This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.

Ages
12 years and older
Gender
Both

Find out more about who can participate in this trial

Trial with
Genentech, Inc.
Start Date
09/23/2020
End Date
07/30/2020

For more information about this study, contact:

Laurie Andrews

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Onyema Ogbuagu, MBBCh, FACP, FIDSA
Associate Professor of Medicine (AIDS)

Sub-Investigator

Thilinie D Bandaranayake, MBBS

Last Updated
10/01/2020
Study HIC
#2000028556

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigator

Contact Information